CYRAMZA demonstrates significant therapeutic benefit in advanced gastric, lung, colorectal, and liver cancers.

Therapeutic Effect

CYRAMZA has shown efficacy in improving clinical outcomes, including progression-free and overall survival, in patients with advanced or metastatic gastric/GEJ adenocarcinoma, NSCLC, mCRC, and HCC. Its anti-angiogenic mechanism disrupts tumor vascularization, thereby inhibiting tumor growth and metastasis. Clinical trials have validated its benefit both as monotherapy and in combination with standard chemotherapeutic agents, with response rates and survival advantages varying by indication and patient population. The therapeutic effect is most pronounced in patients with limited treatment options following progression on prior therapies.